{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:21:39Z","timestamp":1785147699233,"version":"3.55.0"},"reference-count":148,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Multiple myeloma remains an incurable plasma cell cancer with radical case-by-case heterogeneity. Because of this, personalized and disease-specific biology of multiple myeloma must be understood for the discovery of effective molecular targets. The highly evolutionarily conserved Notch signaling pathway has been extensively described as a multifaceted driver of the multiple myeloma disease process\u2014contributing to both intrinsic effects of malignant cells and to widespread remodeling of the tumor microenvironment that further facilitates disease progression. Namely, Notch signaling amongst malignant cells promotes increased proliferation, tumor-initiating capacity, drug resistance, and invasiveness. Moreover, Notch signaling between malignant cells and cells of the tumor microenvironment leads to increased osteodegenerative disease and angiogenesis. This comprehensive review will discuss both the intrinsic implications of pathological Notch signaling in multiple myeloma and the extrinsic implications of Notch signaling in the multiple myeloma tumor microenvironment. Additionally, the genetic origins of Notch signaling dysregulation in multiple myeloma and current attempts at targeting Notch therapeutically will be reviewed. While the subject has been reviewed previously, recent developments in the intervening years demand a revised synthesis of the literature. The aim of this work is to introduce and thoroughly synthesize the current state of knowledge in this vein of research and to highlight future directions for both new and in-the-field scientists.<\/jats:p>","DOI":"10.7717\/peerj.18485","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T10:05:28Z","timestamp":1732788328000},"page":"e18485","source":"Crossref","is-referenced-by-count":3,"title":["A comprehensive review of oncogenic Notch signaling in multiple myeloma"],"prefix":"10.7717","volume":"12","author":[{"given":"Justin","family":"Roosma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"issue":"3","key":"10.7717\/peerj.18485\/ref-1","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.3390\/ijms24032645","article-title":"Recent advances in the applications of small molecules in the treatment of multiple myeloma","volume":"24","author":"Abramson","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41375-019-0519-4","article-title":"Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination","volume":"34","author":"Akhmetzyanova","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"10.7717\/peerj.18485\/ref-3","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2007","journal-title":"Blood"},{"key":"10.7717\/peerj.18485\/ref-4","volume-title":"Survival rates for multiple myeloma","author":"American Cancer Society","year":"2023"},{"issue":"11","key":"10.7717\/peerj.18485\/ref-5","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1002\/jcb.25205","article-title":"Notch signaling promotes osteoclast maturation and resorptive activity","volume":"116","author":"Ashley","year":"2015","journal-title":"Journal of Cellular Biochemistry"},{"issue":"18","key":"10.7717\/peerj.18485\/ref-6","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","article-title":"CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy","volume":"113","author":"Azab","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.7717\/peerj.18485\/ref-7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"11","key":"10.7717\/peerj.18485\/ref-8","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.3390\/ijms18112362","article-title":"ABC transporters in cancer stem cells: beyond chemoresistance","volume":"18","author":"Begicevic","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"issue":"12","key":"10.7717\/peerj.18485\/ref-9","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1002\/mc.22440","article-title":"Multiple myeloma cells modify VEGF\/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch\/miR-223","volume":"55","author":"Berenstein","year":"2016","journal-title":"Molecular Carcinogenesis"},{"issue":"2","key":"10.7717\/peerj.18485\/ref-10","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Current Oncology"},{"issue":"5","key":"10.7717\/peerj.18485\/ref-11","doi-asserted-by":"publisher","first-page":"E402","DOI":"10.1073\/pnas.1416287112","article-title":"Jagged-delta asymmetry in Notch signaling can give rise to a sender\/receiver hybrid phenotype","volume":"112","author":"Boareto","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.7717\/peerj.18485\/ref-12","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/cells10061360","article-title":"Role of 1q21 in multiple myeloma: from pathogenesis to possible therapeutic targets","volume":"10","author":"Burroughs Garc\u00eca","year":"2021","journal-title":"Cells"},{"issue":"22","key":"10.7717\/peerj.18485\/ref-13","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1182\/blood.V128.22.5108.5108","article-title":"Safety and preliminary efficacy results of a phase I first-in-human study of the Novel Notch-1 targeting antibody Brontictuzumab (OMP-52M51) administered intravenously to patients with hematologic malignancies","volume":"128","author":"Casulo","year":"2016","journal-title":"Blood"},{"issue":"14","key":"10.7717\/peerj.18485\/ref-14","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1182\/bloodadvances.2022009387","article-title":"Loss of p 53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cells","volume":"7","author":"Chang","year":"2023","journal-title":"Blood Advances"},{"issue":"4","key":"10.7717\/peerj.18485\/ref-15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.bcmd.2012.01.006","article-title":"Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells","volume":"48","author":"Chiron","year":"2012","journal-title":"Blood Cells, Molecules, and Diseases"},{"issue":"51","key":"10.7717\/peerj.18485\/ref-16","doi-asserted-by":"publisher","first-page":"20778","DOI":"10.1073\/pnas.1019452108","article-title":"Notch1 regulates the expression of the multidrug resistance gene ABCC1\/MRP1 in cultured cancer cells","volume":"108","author":"Cho","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"43","key":"10.7717\/peerj.18485\/ref-17","doi-asserted-by":"publisher","first-page":"17380","DOI":"10.1073\/pnas.1304266110","article-title":"Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity","volume":"110","author":"Christianson","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.7717\/peerj.18485\/ref-18","doi-asserted-by":"publisher","first-page":"e886718","DOI":"10.3389\/fcell.2022.886718","article-title":"Recombination: recent insights in formation of the recombinase complex and recruitment of DNA repair machinery","volume":"10","author":"Christie","year":"2022","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"35","key":"10.7717\/peerj.18485\/ref-19","doi-asserted-by":"publisher","first-page":"56013","DOI":"10.18632\/oncotarget.10820","article-title":"Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche","volume":"7","author":"Colombo","year":"2016","journal-title":"Oncotarget"},{"issue":"29","key":"10.7717\/peerj.18485\/ref-20","doi-asserted-by":"publisher","first-page":"26826","DOI":"10.18632\/oncotarget.5025","article-title":"Notch signaling deregulation in multiple myeloma: a rational molecular target","volume":"6","author":"Colombo","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.7717\/peerj.18485\/ref-21","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.3324\/haematol.2019.221077","article-title":"Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance","volume":"105","author":"Colombo","year":"2020","journal-title":"Haematologica"},{"issue":"13","key":"10.7717\/peerj.18485\/ref-22","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.3390\/ijms20133236","article-title":"Extracellular vesicles enhance multiple myeloma metastatic dissemination","volume":"20","author":"Colombo","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"issue":"21","key":"10.7717\/peerj.18485\/ref-23","doi-asserted-by":"publisher","first-page":"10393","DOI":"10.18632\/oncotarget.2084","article-title":"Notch signaling drives multiple myeloma induced osteoclastogenesis","volume":"5","author":"Colombo","year":"2014","journal-title":"Oncotarget"},{"issue":"19","key":"10.7717\/peerj.18485\/ref-24","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.2106\/JBJS.M.01096","article-title":"Current concepts review: a review of osteocyte function and the emerging importance of sclerostin","volume":"96","author":"Compton","year":"2014","journal-title":"Journal of Bone and Joint Surgery"},{"issue":"June","key":"10.7717\/peerj.18485\/ref-25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fendo.2018.00313","article-title":"Role of tumor-derived chemokines in osteolytic bone metastasis","volume":"9","author":"Coniglio","year":"2018","journal-title":"Frontiers in Endocrinology"},{"issue":"9","key":"10.7717\/peerj.18485\/ref-26","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncology"},{"issue":"5","key":"10.7717\/peerj.18485\/ref-27","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","article-title":"Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines","volume":"93","author":"Damiano","year":"1999","journal-title":"Blood"},{"key":"10.7717\/peerj.18485\/ref-28","doi-asserted-by":"publisher","first-page":"v540","DOI":"10.1093\/annonc\/mdx386.004","article-title":"Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2\/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)","volume":"28","author":"Daniel","year":"2017","journal-title":"Annals of Oncology"},{"issue":"13","key":"10.7717\/peerj.18485\/ref-29","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1182\/blood-2003-01-0016","article-title":"Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis","volume":"102","author":"Davies","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canlet.2016.04.024","article-title":"Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity","volume":"377","author":"De Veirman","year":"2016","journal-title":"Cancer Letters"},{"issue":"5","key":"10.7717\/peerj.18485\/ref-31","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"76","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Research"},{"issue":"4","key":"10.7717\/peerj.18485\/ref-32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40610-015-0026-y","article-title":"Osteocytes and skeletal pathophysiology","volume":"1","author":"Delgado-Calle","year":"2015","journal-title":"Current Molecular Biology Reports"},{"issue":"4","key":"10.7717\/peerj.18485\/ref-33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.bbrc.2015.10.076","article-title":"Notch increased vitronection adhesion protects myeloma cells from drug induced apoptosis","volume":"467","author":"Ding","year":"2015","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4314\/tjpr.v23i1.1","article-title":"Mir-186 inhibits the proliferation and growth of multiple myeloma cells by targeting Jagged-1 expression","volume":"23","author":"Dong","year":"2024","journal-title":"Tropical Journal of Pharmaceutical Research"},{"issue":"May","key":"10.7717\/peerj.18485\/ref-35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fendo.2018.00218","article-title":"Soluble and cell-cell-mediated drivers of proteasome inhibitor resistance in multiple myeloma","volume":"9","author":"Farrell","year":"2018","journal-title":"Frontiers in Endocrinology"},{"issue":"11","key":"10.7717\/peerj.18485\/ref-36","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1084\/jem.20132528","article-title":"Specific fibroblastic niches in secondary lymphoid organs orchestrate distinct Notch-regulated immune responses","volume":"211","author":"Fasnacht","year":"2014","journal-title":"Journal of Experimental Medicine"},{"issue":"3","key":"10.7717\/peerj.18485\/ref-37","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2165\/00003495-199141030-00007","article-title":"Mitoxantrone","volume":"41","author":"Faulds","year":"1991","journal-title":"Drugs"},{"issue":"7","key":"10.7717\/peerj.18485\/ref-38","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/annonc\/mdy171","article-title":"A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors","volume":"29","author":"Ferrarotto","year":"2018","journal-title":"Annals of Oncology"},{"issue":"23","key":"10.7717\/peerj.18485\/ref-39","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1182\/blood.V126.23.2974.2974","article-title":"CD138 regulates myeloma cell survival, proliferation, BM engraftment and tumor organization","volume":"126","author":"Fooksman","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/dvdy.20603","article-title":"Buried alive: how osteoblasts become osteocytes","volume":"235","author":"Franz-Odendaal","year":"2006","journal-title":"Developmental Dynamics"},{"issue":"3","key":"10.7717\/peerj.18485\/ref-41","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/leu.2015.289","article-title":"Halting pro-survival autophagy by TGF\u03b2 inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients","volume":"30","author":"Frassanito","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.7717\/peerj.18485\/ref-42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3892\/ol.2023.14059","article-title":"p21 promotes gemcitabine tolerance in A549 cells by inhibiting DNA damage and altering the cell cycle","volume":"26","author":"Fu","year":"2023","journal-title":"Oncology Letters"},{"issue":"20","key":"10.7717\/peerj.18485\/ref-43","doi-asserted-by":"publisher","first-page":"6402","DOI":"10.1128\/MCB.00299-08","article-title":"The association of Notch2 and NF-\u03baB accelerates RANKL-induced osteoclastogenesis","volume":"28","author":"Fukushima","year":"2008","journal-title":"Molecular and Cellular Biology"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/cam4.1181","article-title":"The mechanism study of miR-125b in occurrence and progression of multiple myeloma","volume":"7","author":"Gao","year":"2018","journal-title":"Cancer Medicine"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-45","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1186\/s12935-016-0326-1","article-title":"Survivin: a unique target for tumor therapy","volume":"16","author":"Garg","year":"2016","journal-title":"Cancer Cell International"},{"key":"10.7717\/peerj.18485\/ref-46","doi-asserted-by":"publisher","first-page":"e609324","DOI":"10.3389\/fimmu.2020.609324","article-title":"Notch signaling in B cell immune responses","volume":"11","author":"Garis","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"9","key":"10.7717\/peerj.18485\/ref-47","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3324\/haematol.2021.279716","article-title":"Extracellular vesicles mediate the communication between multiple myeloma and bone marrow microenvironment in a NOTCH dependent way","volume":"107","author":"Giannandrea","year":"2022","journal-title":"Haematologica"},{"issue":"11","key":"10.7717\/peerj.18485\/ref-48","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1038\/leu.2017.102","article-title":"Proteomic characterization of human multiple myeloma bone marrow extracellular matrix","volume":"31","author":"Glavey","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41589-022-01113-4","article-title":"Affinity-matured DLL4 ligands as broad-spectrum modulators of Notch signaling","volume":"19","author":"Gonzalez-Perez","year":"2023","journal-title":"Nature Chemical Biology"},{"issue":"9","key":"10.7717\/peerj.18485\/ref-50","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1182\/blood-2007-02-069625","article-title":"Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma","volume":"110","author":"Gonz\u00e1lez","year":"2007","journal-title":"Blood"},{"key":"10.7717\/peerj.18485\/ref-51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11912-019-0754-x","article-title":"Plasma cell leukemia: definition, presentation, and treatment","volume":"21","author":"Gundesen","year":"2019","journal-title":"Current Oncology Reports"},{"issue":"33","key":"10.7717\/peerj.18485\/ref-52","doi-asserted-by":"publisher","first-page":"55405","DOI":"10.18632\/oncotarget.19265","article-title":"Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"key":"10.7717\/peerj.18485\/ref-53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semcdb.2020.05.019","article-title":"The substrate repertoire of \u03b3-secretase\/presenilin","volume":"105","author":"G\u00fcner","year":"2020","journal-title":"Seminars in Cell and Developmental Biology"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3233\/JAD-2011-101065","article-title":"The many substrates of presenilin\/\u03b3-secretase","volume":"25","author":"Haapasalo","year":"2011","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"494","key":"10.7717\/peerj.18485\/ref-55","doi-asserted-by":"publisher","first-page":"289412","DOI":"10.1126\/scitranslmed.aau6246","article-title":"Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition","volume":"11","author":"Habets","year":"2019","journal-title":"Science Translational Medicine"},{"issue":"January","key":"10.7717\/peerj.18485\/ref-56","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3389\/fendo.2018.00788","article-title":"Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma","volume":"10","author":"Harmer","year":"2019","journal-title":"Frontiers in Endocrinology"},{"issue":"11","key":"10.7717\/peerj.18485\/ref-57","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/rheumatology\/ken363","article-title":"IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-\u03b1 and IL-17","volume":"47","author":"Hashizume","year":"2008","journal-title":"Rheumatology"},{"issue":"12","key":"10.7717\/peerj.18485\/ref-58","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1182\/blood-2003-12-4114","article-title":"Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines","volume":"104","author":"Houde","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.57352\/ijm.10.1_1","article-title":"Notch1-JAG1 signaling induces aggressive myeloma cell behaviors","volume":"10","author":"Ishibashi","year":"2020","journal-title":"International Journal of Myeloma"},{"key":"10.7717\/peerj.18485\/ref-60","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"9","key":"10.7717\/peerj.18485\/ref-61","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.prp.2018.07.025","article-title":"miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1","volume":"214","author":"Jia","year":"2018","journal-title":"Pathology Research and Practice"},{"issue":"9","key":"10.7717\/peerj.18485\/ref-62","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1182\/blood-2003-07-2254","article-title":"Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells","volume":"103","author":"Jundt","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.7717\/peerj.18485\/ref-63","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1038\/oncsis.2016.5","article-title":"Heparanase-induced shedding of syndecan-1\/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins","volume":"5","author":"Jung","year":"2016","journal-title":"Oncogenesis"},{"issue":"2","key":"10.7717\/peerj.18485\/ref-64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2013-03-487884","article-title":"Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma","volume":"122","author":"Kaiser","year":"2013","journal-title":"Blood"},{"issue":"43","key":"10.7717\/peerj.18485\/ref-65","doi-asserted-by":"publisher","first-page":"14710","DOI":"10.1074\/jbc.RA120.014407","article-title":"Canonical notch ligands and fringes have distinct effects on NOTCH1 and NOTCH2","volume":"295","author":"Kakuda","year":"2020","journal-title":"Journal of Biological Chemistry"},{"issue":"4","key":"10.7717\/peerj.18485\/ref-66","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/imm.12333","article-title":"Notch1 is an important mediator for enhancing of B-cell activation and antibody secretion by Notch ligand","volume":"143","author":"Kang","year":"2014","journal-title":"Immunology"},{"issue":"4","key":"10.7717\/peerj.18485\/ref-67","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1038\/bcj.2012.10","article-title":"Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo","volume":"2","author":"Kiziltepe","year":"2012","journal-title":"Blood Cancer Journal"},{"issue":"2","key":"10.7717\/peerj.18485\/ref-68","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cell.2009.03.045","article-title":"The canonical notch signaling pathway: unfolding the activation mechanism","volume":"137","author":"Kopan","year":"2009","journal-title":"Cell"},{"issue":"6168","key":"10.7717\/peerj.18485\/ref-69","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"issue":"19","key":"10.7717\/peerj.18485\/ref-70","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1200\/JCO.2011.39.1540","article-title":"Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors","volume":"30","author":"Krop","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.7717\/peerj.18485\/ref-71","doi-asserted-by":"publisher","first-page":"e22585","DOI":"10.7759\/cureus.22585","article-title":"Multiple myeloma and renal failure: mechanisms, diagnosis, and management","volume":"14","author":"Kundu","year":"2022","journal-title":"Cureus"},{"issue":"3","key":"10.7717\/peerj.18485\/ref-72","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/cncr.29055","article-title":"Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933","volume":"121","author":"Lee","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.7717\/peerj.18485\/ref-73","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3390\/ijms24021341","article-title":"S100A6 protein\u2014expression and function in norm and pathology","volume":"24","author":"Le\u015bniak","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"12","key":"10.7717\/peerj.18485\/ref-74","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1158\/1535-7163.MCT-10-0372","article-title":"Combined inhibition of Notch signaling and Bcl-2\/Bcl-xL results in synergistic antimyeloma effect","volume":"9","author":"Li","year":"2010","journal-title":"Molecular Cancer Therapeutics"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13045-023-01439-z","article-title":"The Notch signaling pathway: a potential target for cancer immunotherapy","volume":"16","author":"Li","year":"2023","journal-title":"Journal of Hematology and Oncology"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-76","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41598-022-24353-9","article-title":"C1QA, C1QB, and GZMB are novel prognostic biomarkers of skin cutaneous melanoma relating tumor microenvironment","volume":"12","author":"Liang","year":"2022","journal-title":"Scientific Reports"},{"issue":"5","key":"10.7717\/peerj.18485\/ref-77","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.19746\/j.cnki.issn1009-2137.2022.05.026","article-title":"IL-6 regulates the chemosensitivity of drug-resistant multiple myeloma cell lines to bortezomib through STAT3\/Notch signaling pathway","volume":"30","author":"Liu","year":"2022","journal-title":"Journal of Experimental Hematology"},{"issue":"3","key":"10.7717\/peerj.18485\/ref-78","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.bbrc.2015.11.136","article-title":"MiR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1","volume":"469","author":"Liu","year":"2016","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"9","key":"10.7717\/peerj.18485\/ref-79","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment","volume":"25","author":"Ludwig","year":"2020","journal-title":"The Oncologist"},{"key":"10.7717\/peerj.18485\/ref-80","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41408-023-00907-6","article-title":"Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival","volume":"13","author":"Maichl","year":"2023","journal-title":"Blood Cancer Journal"},{"issue":"11","key":"10.7717\/peerj.18485\/ref-81","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1158\/1535-7163.MCT-18-1176","article-title":"Development of therapeutic anti-Jagged1 antibodies for cancer therapy","volume":"18","author":"Masiero","year":"2019","journal-title":"Molecular Cancer Therapeutics"},{"issue":"12","key":"10.7717\/peerj.18485\/ref-82","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.tips.2023.09.011","article-title":"New tricks for an old pathway: emerging Notch-based biotechnologies and therapeutics","volume":"44","author":"Medina","year":"2023","journal-title":"Trends in Pharmacological Sciences"},{"issue":"12","key":"10.7717\/peerj.18485\/ref-83","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1172\/JCI9133","article-title":"Paget\u2019s disease and IL-6","volume":"105","author":"Menaa","year":"2000","journal-title":"The Journal of Clinical Investigation"},{"issue":"2","key":"10.7717\/peerj.18485\/ref-84","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41388-018-0465-z","article-title":"Gamma-secretase-dependent signaling of receptor tyrosine kinases","volume":"38","author":"Merilahti","year":"2019","journal-title":"Oncogene"},{"issue":"2","key":"10.7717\/peerj.18485\/ref-85","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bph.16028","article-title":"Stromal bone marrow fibroblasts and mesenchymal stem cells support acute myeloid leukaemia cells and promote therapy resistance","volume":"181","author":"Miari","year":"2023","journal-title":"British Journal of Pharmacology"},{"issue":"7","key":"10.7717\/peerj.18485\/ref-86","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/leu.2013.27","article-title":"Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4\/SDF-1","volume":"27","author":"Mirandola","year":"2013","journal-title":"Leukemia"},{"issue":"7270","key":"10.7717\/peerj.18485\/ref-87","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nature08543","article-title":"Direct inhibition of the NOTCH transcription factor complex","volume":"462","author":"Moellering","year":"2009","journal-title":"Nature"},{"issue":"9","key":"10.7717\/peerj.18485\/ref-88","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1007\/s00018-021-03767-0","article-title":"Morphogens and growth factor signalling in the myeloma bone-lining niche","volume":"78","author":"Morris","year":"2021","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"12","key":"10.7717\/peerj.18485\/ref-89","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41408-017-0001-3","article-title":"Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells","volume":"7","author":"Muguruma","year":"2017","journal-title":"Blood Cancer Journal"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-90","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41598-017-19073-4","article-title":"Targeting insulin-like growth factor-I and extracellular matrix interactions in melanoma progression","volume":"8","author":"Murekatete","year":"2018","journal-title":"Scientific Reports"},{"issue":"7","key":"10.7717\/peerj.18485\/ref-91","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/sj.bjc.6605289","article-title":"S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility","volume":"101","author":"Nedjadi","year":"2009","journal-title":"British Journal of Cancer"},{"issue":"9","key":"10.7717\/peerj.18485\/ref-92","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood-2003-07-2340","article-title":"Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines","volume":"103","author":"Nefedova","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.7717\/peerj.18485\/ref-93","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2007-07-102632","article-title":"Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy","volume":"111","author":"Nefedova","year":"2008","journal-title":"Blood"},{"issue":"18","key":"10.7717\/peerj.18485\/ref-94","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1101\/gad.827900","article-title":"The glucocorticoid receptor inhibits NF\u03baB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain","volume":"14","author":"Nissen","year":"2000","journal-title":"Genes and Development"},{"issue":"12","key":"10.7717\/peerj.18485\/ref-95","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.7717\/peerj.18485\/ref-96","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1097\/JTO.0b013e31818dda9d","article-title":"The CXCR4\/SDF-1 chemokine receptor axis a new target therapeutic for non-small cell lung cancer","volume":"3","author":"Otsuka","year":"2008","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-97","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/medsci9010003","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Medical Sciences (Basel, Switzerland)"},{"issue":"9","key":"10.7717\/peerj.18485\/ref-98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12092600","article-title":"Jagged ligands enhance the pro-angiogenic activity of multiple myeloma cells","volume":"12","author":"Palano","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.7717\/peerj.18485\/ref-99","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.yexcr.2003.12.003","article-title":"Integrin \u03b14\u03b21 involvement in stromal cell-derived factor-1\u03b1-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion","volume":"294","author":"Parmo-Caba\u00f1as","year":"2004","journal-title":"Experimental Cell Research"},{"key":"10.7717\/peerj.18485\/ref-100","article-title":"Exploring mechanisms of drug resistance in multiple myeloma: the roles of the progenitor compartment, APRIL and Notch signaling","author":"Percy","year":"2015"},{"issue":"19","key":"10.7717\/peerj.18485\/ref-101","doi-asserted-by":"publisher","first-page":"14558","DOI":"10.3390\/ijms241914558","article-title":"The potential of JAG ligands as therapeutic targets and predictive biomarkers in multiple myeloma","volume":"24","author":"Platonova","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"999","key":"10.7717\/peerj.18485\/ref-102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1381612822666161006160524","article-title":"Targeting Notch as a therapeutic approach for human malignancies","volume":"22","author":"Platonova","year":"2016","journal-title":"Current Pharmaceutical Design"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-103","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1038\/onc.2009.46","article-title":"Noxa: at the tip of the balance between life and death","volume":"27","author":"Ploner","year":"2008","journal-title":"Oncogene"},{"issue":"9","key":"10.7717\/peerj.18485\/ref-104","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3390\/jcm10091841","article-title":"Treatment of multiple myeloma and the role of melphalan in the era of modern therapies\u2014current research and clinical approaches","volume":"10","author":"Poczta","year":"2021","journal-title":"Journal of Clinical Medicine"},{"issue":"4","key":"10.7717\/peerj.18485\/ref-105","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1074\/jbc.M115.686295","article-title":"Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell interactions","volume":"291","author":"Purushothaman","year":"2016","journal-title":"Journal of Biological Chemistry"},{"key":"10.7717\/peerj.18485\/ref-106","first-page":"331","article-title":"Heparanase: a dynamic promoter of myeloma progression","volume-title":"Advances in Experimental Medicine and Biology","volume":"1221","author":"Purushothaman","year":"2020"},{"key":"10.7717\/peerj.18485\/ref-107","doi-asserted-by":"publisher","first-page":"e418-23","DOI":"10.1200\/EDBK_159009","article-title":"Updated diagnostic criteria and staging system for multiple myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"9","key":"10.7717\/peerj.18485\/ref-108","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"American Journal of Hematology"},{"issue":"2","key":"10.7717\/peerj.18485\/ref-109","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/leu.2011.192","article-title":"MRK003, a \u03b3-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin\u2019s lymphoma","volume":"26","author":"Ramakrishnan","year":"2012","journal-title":"Leukemia"},{"issue":"8","key":"10.7717\/peerj.18485\/ref-110","doi-asserted-by":"publisher","first-page":"6490","DOI":"10.1074\/jbc.M110.183277","article-title":"Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity","volume":"286","author":"Ramani","year":"2011","journal-title":"Journal of Biological Chemistry"},{"issue":"7","key":"10.7717\/peerj.18485\/ref-111","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2007-09-078162","article-title":"Bcl-2-family proteins and hematologic malignancies: history and future prospects","volume":"111","author":"Reed","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.7717\/peerj.18485\/ref-112","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/10428194.2022.2136950","article-title":"From mechanism to resistance\u2014changes in the use of dexamethasone in the treatment of multiple myeloma","volume":"64","author":"Rosenberg","year":"2023","journal-title":"Leukemia and Lymphoma"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-113","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/cyto.a.22355","article-title":"Tracking plasma cell differentiation and survival","volume":"85","author":"Roth","year":"2014","journal-title":"Cytometry Part A"},{"issue":"4","key":"10.7717\/peerj.18485\/ref-114","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/cr.2015.29","article-title":"Heparanase activates the syndecan-syntenin-ALIX exosome pathway","volume":"25","author":"Roucourt","year":"2015","journal-title":"Cell Research"},{"key":"10.7717\/peerj.18485\/ref-115","doi-asserted-by":"publisher","first-page":"100785","DOI":"10.1016\/j.neo.2022.100785","article-title":"Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction","volume":"28","author":"Sabol","year":"2022","journal-title":"Neoplasia (United States)"},{"issue":"19","key":"10.7717\/peerj.18485\/ref-116","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1158\/0008-5472.CAN-21-0524","article-title":"Targeting notch inhibitors to the myeloma bone marrow niche decreases tumor growth and bone destruction without gut toxicity","volume":"81","author":"Sabol","year":"2021","journal-title":"Cancer Research"},{"issue":"5","key":"10.7717\/peerj.18485\/ref-117","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/s1074-7613(03)00111-0","article-title":"Notch2 Is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development","volume":"18","author":"Saito","year":"2003","journal-title":"Immunity"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-118","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.neo.2018.10.011","article-title":"Homotypic and heterotypic activation of the Notch pathway in multiple myeloma\u2014enhanced angiogenesis: a novel therapeutic target?","volume":"21","author":"Saltarella","year":"2019","journal-title":"Neoplasia (United States)"},{"issue":"11","key":"10.7717\/peerj.18485\/ref-119","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.3390\/cells10113185","article-title":"Role of extracellular vesicle-based cell-to-cell communication in multiple myeloma progression","volume":"10","author":"Saltarella","year":"2021","journal-title":"Cells"},{"issue":"39","key":"10.7717\/peerj.18485\/ref-120","doi-asserted-by":"publisher","first-page":"15454","DOI":"10.1073\/pnas.0702891104","article-title":"Notch1 engagement by Delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cells","volume":"104","author":"Santos","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.7717\/peerj.18485\/ref-121","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2174\/156720512799361600","article-title":"An overview of notch signaling in adult tissue renewal and maintenance","volume":"9","author":"Sato","year":"2012","journal-title":"Current Alzheimer Research"},{"issue":"12","key":"10.7717\/peerj.18485\/ref-122","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/leu.2008.135","article-title":"Notch inhibition blocks multiple myeloma cell-induced osteoclast activation","volume":"22","author":"Schwarzer","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"10.7717\/peerj.18485\/ref-123","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1038\/bcj.2014.37","article-title":"Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model","volume":"4","author":"Schwarzer","year":"2014","journal-title":"Blood Cancer Journal"},{"issue":"6","key":"10.7717\/peerj.18485\/ref-124","doi-asserted-by":"publisher","first-page":"104794","DOI":"10.1016\/j.jbc.2023.104794","article-title":"Selective inhibitors of the PSEN1-gamma-secretase complex","volume":"299","author":"Serneels","year":"2023","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-125","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.imlet.2008.08.001","article-title":"Expression of Delta-like 1 in the splenic non-hematopoietic cells is essential for marginal zone B cell development","volume":"121","author":"Sheng","year":"2008","journal-title":"Immunology Letters"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-126","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"20","key":"10.7717\/peerj.18485\/ref-127","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1158\/0008-5472.CAN-17-0357","article-title":"Anti-Jagged immunotherapy inhibits MDSCs and overcomes tumor-induced tolerance","volume":"77","author":"Sierra","year":"2017","journal-title":"Cancer Research"},{"issue":"12","key":"10.7717\/peerj.18485\/ref-128","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/j.humpath.2010.05.002","article-title":"Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"41","author":"\u0160krti\u0107","year":"2010","journal-title":"Human Pathology"},{"issue":"4","key":"10.7717\/peerj.18485\/ref-129","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s10637-018-0714-6","article-title":"A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors","volume":"37","author":"Smith","year":"2019","journal-title":"Investigational New Drugs"},{"issue":"5","key":"10.7717\/peerj.18485\/ref-130","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/ni793","article-title":"Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells","volume":"3","author":"Tanigaki","year":"2002","journal-title":"Nature Immunology"},{"issue":"8","key":"10.7717\/peerj.18485\/ref-131","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1182\/blood-2006-09-046698","article-title":"Notch activity synergizes with B-cell-receptor and CD40 signaling to enhance B-cell activation","volume":"109","author":"Thomas","year":"2007","journal-title":"Blood"},{"issue":"14","key":"10.7717\/peerj.18485\/ref-132","doi-asserted-by":"publisher","first-page":"10093","DOI":"10.1074\/jbc.C112.444562","article-title":"Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes","volume":"288","author":"Thompson","year":"2013","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-133","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Th\u00e9ry","year":"2018","journal-title":"Journal of Extracellular Vesicles"},{"key":"10.7717\/peerj.18485\/ref-134","doi-asserted-by":"publisher","first-page":"100253","DOI":"10.1016\/j.jbo.2019.100253","article-title":"The role of CXCR4 in multiple myeloma: Cells\u2019 journey from bone marrow to beyond","volume":"17","author":"Ullah","year":"2019","journal-title":"Journal of Bone Oncology"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-135","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.exphem.2008.08.006","article-title":"Identification of primary MAFB target genes in multiple myeloma","volume":"37","author":"van Stralen","year":"2009","journal-title":"Experimental Hematology"},{"issue":"6","key":"10.7717\/peerj.18485\/ref-136","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discovery"},{"issue":"25","key":"10.7717\/peerj.18485\/ref-137","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.7717\/peerj.18485\/ref-138","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3390\/life12060812","article-title":"Review of multiple myeloma genetics including effects on prognosis, response to treatment, and diagnostic workup","volume":"12","author":"Wiedmeier-Nutor","year":"2022","journal-title":"Life"},{"issue":"12","key":"10.7717\/peerj.18485\/ref-139","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1038\/leu.2012.126","article-title":"Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway","volume":"26","author":"Xu","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.7717\/peerj.18485\/ref-140","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.bbrc.2012.10.071","article-title":"Dll1\/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma","volume":"428","author":"Xu","year":"2012","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"6","key":"10.7717\/peerj.18485\/ref-141","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/leu.2011.332","article-title":"Dll1\/Notch activation accelerates multiple myeloma disease development by promoting CD138 + MM-cell proliferation","volume":"26","author":"Xu","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"10.7717\/peerj.18485\/ref-142","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/leu.2014.255","article-title":"Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma","volume":"29","author":"Yang","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.7717\/peerj.18485\/ref-143","doi-asserted-by":"publisher","first-page":"279","DOI":"10.14310\/horm.2002.1111024","article-title":"The role of the Wnt signaling pathway in osteoblast commitment and differentiation","volume":"6","author":"Yavropoulou","year":"2007","journal-title":"Hormones"},{"issue":"1","key":"10.7717\/peerj.18485\/ref-144","doi-asserted-by":"publisher","first-page":"352","DOI":"10.4049\/jimmunol.0803183","article-title":"Notch ligands expressed by follicular dendritic cells protect germinal center B cells from apoptosis","volume":"183","author":"Yoon","year":"2009","journal-title":"The Journal of Immunology"},{"issue":"5","key":"10.7717\/peerj.18485\/ref-145","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-04-1687","article-title":"Elevated serum levels of stromal-derived factor-1A are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients","volume":"65","author":"Zannettino","year":"2005","journal-title":"Cancer Research"},{"issue":"3","key":"10.7717\/peerj.18485\/ref-146","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1210\/er.2016-1002","article-title":"Notch signaling and the skeleton","volume":"37","author":"Zanotti","year":"2016","journal-title":"Endocrine Reviews"},{"issue":"6","key":"10.7717\/peerj.18485\/ref-147","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ccell.2017.11.002","article-title":"Therapeutic antibody targeting tumor- and osteoblastic niche-derived Jagged1 sensitizes bone metastasis to chemotherapy","volume":"32","author":"Zheng","year":"2017","journal-title":"Cancer Cell"},{"key":"10.7717\/peerj.18485\/ref-148","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molimm.2017.08.021","article-title":"Both Notch1 and its ligands in B cells promote antibody production","volume":"91","author":"Zhu","year":"2017","journal-title":"Molecular Immunology"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/18485.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/18485.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/18485.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/18485.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T10:05:34Z","timestamp":1732788334000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/18485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":148,"alternative-id":["10.7717\/peerj.18485"],"URL":"https:\/\/doi.org\/10.7717\/peerj.18485","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"article-number":"e18485"}}